Recurrent Meningioma Clinical Trials

7 recruiting

About Recurrent Meningioma Clinical Trials

Looking for clinical trials for Recurrent Meningioma? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Meningioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Meningioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
Alliance for Clinical Trials in Oncology124 enrolled781 locationsNCT02523014
Recruiting
Phase 1Phase 2

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Recurrent Meningioma
Joshua Palmer30 enrolled1 locationNCT07150806
Recruiting
Phase 2

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Grade 2 MeningiomaRecurrent MeningiomaGrade 1 Meningioma+2 more
Mayo Clinic41 enrolled1 locationNCT04082520
Recruiting
Phase 2

177Lu-DOTATATE for Recurrent Meningioma

Recurrent Meningioma
European Organisation for Research and Treatment of Cancer - EORTC136 enrolled12 locationsNCT06326190
Recruiting
Phase 2

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Grade II MeningiomaGrade III MeningiomaAtypical Meningioma+3 more
Northwestern University27 enrolled8 locationsNCT02847559
Recruiting
Phase 2

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

Grade I Meningioma, AdultGrade II Meningioma, AdultGrade III Meningioma, Adult+1 more
Nancy Ann Oberheim Bush, MD37 enrolled1 locationNCT04659811
Recruiting
Not Applicable

Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma

MeningiomaRecurrent MeningiomaMeningioma, Malignant
University of California, San Francisco23 enrolled1 locationNCT06557512